Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, 18-75 years of age;~* type 2 diabetes treated with a stable dose of metformin and sulphonylurea for at least 12 weeks;~* C-peptide (fasting) \>=1.0ng/mL;~* HbA1c \>=7.0% and \<=10.0% at screening;~* BMI \>=25 (\>23 for Asians) and \<=45kg/m2 at screening;~* stable weight +-5% for at least 12 weeks prior to screening.~Exclusion Criteria:~* history of type 1 diabetes mellitus or acute metabolic diabetic complications such as ketoacidosis or hyperosmolar coma in the previous 6 months;~* evidence of clinically significant diabetic complications;~* symptomatic poorly controlled diabetes;~* clinically symptomatic gastrointestinal disease;~* myocardial infarction, coronary artery bypass surgery, post-transplantation cardiomyopathy or stroke within the previous 6 months;~* known hemoglobinopathy or chronic anemia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- insulin glargine (Type: ACTIVE_COMPARATOR): insulin glargine starting dose 10 IU daily in addition to continued prestudy metformin treatment
- taspoglutide 10 mg (Type: EXPERIMENTAL): taspoglutide 10 mg once weekly in addition to continued prestudy metformin treatment
- taspoglutide 10 mg/20 mg (Type: EXPERIMENTAL): taspoglutide 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly) in addition to continued prestudy metformin treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).